Cargando…
A multiple sclerosis disease progression measure based on cumulative disability
BACKGROUND: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. OBJECTIVE: The objective of this study is to create a severity metric that can reliably summarize a patient’s disease cour...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521354/ https://www.ncbi.nlm.nih.gov/pubmed/33487091 http://dx.doi.org/10.1177/1352458520988632 |
_version_ | 1784584882786140160 |
---|---|
author | Manouchehrinia, Ali Kingwell, Elaine Zhu, Feng Tremlett, Helen Hillert, Jan Ramanujam, Ryan |
author_facet | Manouchehrinia, Ali Kingwell, Elaine Zhu, Feng Tremlett, Helen Hillert, Jan Ramanujam, Ryan |
author_sort | Manouchehrinia, Ali |
collection | PubMed |
description | BACKGROUND: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. OBJECTIVE: The objective of this study is to create a severity metric that can reliably summarize a patient’s disease course. METHODS: We developed the nARMSS – normalized ARMSS (age-related MS severity score) over follow-up, using the deviation of individual ARMSS scores from the expected value and integrated over the corresponding time period. The nARMSS scales from −5 to +5; a positive value indicates a more severe disease course for a patient when compared to other patients with similar disease timings. RESULTS: Using Swedish MS registry data, the nARMSS was tested using data at 2 and 4 years of follow-up to predict the most severe quartile during the subsequent period up to 10 years total follow-up. The metric used was area under the curve of the receiver operating characteristic (AUC-ROC). This resulted in measurements of 0.929 and 0.941. In an external Canadian validation cohort, the equivalent AUC-ROCs were 0.901 and 0.908. CONCLUSION: The nARMSS provides a reliable, generalizable and easily measurable metric which makes longitudinal comparison of disease course between individuals feasible. |
format | Online Article Text |
id | pubmed-8521354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-85213542021-10-19 A multiple sclerosis disease progression measure based on cumulative disability Manouchehrinia, Ali Kingwell, Elaine Zhu, Feng Tremlett, Helen Hillert, Jan Ramanujam, Ryan Mult Scler Original Research Papers BACKGROUND: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. OBJECTIVE: The objective of this study is to create a severity metric that can reliably summarize a patient’s disease course. METHODS: We developed the nARMSS – normalized ARMSS (age-related MS severity score) over follow-up, using the deviation of individual ARMSS scores from the expected value and integrated over the corresponding time period. The nARMSS scales from −5 to +5; a positive value indicates a more severe disease course for a patient when compared to other patients with similar disease timings. RESULTS: Using Swedish MS registry data, the nARMSS was tested using data at 2 and 4 years of follow-up to predict the most severe quartile during the subsequent period up to 10 years total follow-up. The metric used was area under the curve of the receiver operating characteristic (AUC-ROC). This resulted in measurements of 0.929 and 0.941. In an external Canadian validation cohort, the equivalent AUC-ROCs were 0.901 and 0.908. CONCLUSION: The nARMSS provides a reliable, generalizable and easily measurable metric which makes longitudinal comparison of disease course between individuals feasible. SAGE Publications 2021-01-25 2021-10 /pmc/articles/PMC8521354/ /pubmed/33487091 http://dx.doi.org/10.1177/1352458520988632 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Papers Manouchehrinia, Ali Kingwell, Elaine Zhu, Feng Tremlett, Helen Hillert, Jan Ramanujam, Ryan A multiple sclerosis disease progression measure based on cumulative disability |
title | A multiple sclerosis disease progression measure based on cumulative disability |
title_full | A multiple sclerosis disease progression measure based on cumulative disability |
title_fullStr | A multiple sclerosis disease progression measure based on cumulative disability |
title_full_unstemmed | A multiple sclerosis disease progression measure based on cumulative disability |
title_short | A multiple sclerosis disease progression measure based on cumulative disability |
title_sort | multiple sclerosis disease progression measure based on cumulative disability |
topic | Original Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521354/ https://www.ncbi.nlm.nih.gov/pubmed/33487091 http://dx.doi.org/10.1177/1352458520988632 |
work_keys_str_mv | AT manouchehriniaali amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT kingwellelaine amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT zhufeng amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT tremletthelen amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT hillertjan amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT ramanujamryan amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT manouchehriniaali multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT kingwellelaine multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT zhufeng multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT tremletthelen multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT hillertjan multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability AT ramanujamryan multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability |